$TRDA
Entrada Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000155837021016637 Filed on December 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.098M $3.851M $1.273M
YoY Change 205.36% 202.51%
% of Gross Profit
Research & Development $12.36M $10.51M $5.700M
YoY Change 85.73% 84.44%
% of Gross Profit
Depreciation & Amortization $364.0K $300.0K $100.0K
YoY Change 271.43% 200.0%
% of Gross Profit
Operating Expenses $18.46M $14.36M $6.973M
YoY Change 113.34% 105.99%
Operating Profit -$14.36M -$6.973M
YoY Change 105.99%
Interest Expense $13.00K -$66.00K -$17.00K
YoY Change -165.0% 288.24%
% of Operating Profit
Other Income/Expense, Net -$66.00K -$17.00K
YoY Change 288.24%
Pretax Income -$18.45M -$14.43M -$6.990M
YoY Change 112.69% 106.44%
Income Tax
% Of Pretax Income
Net Earnings -$18.45M -$14.43M -$6.990M
YoY Change 112.69% 106.44%
Net Earnings / Revenue
Basic Earnings Per Share -$9.78 -$6.13
Diluted Earnings Per Share -$2.943M -$9.78 -$6.13
COMMON SHARES
Basic Shares Outstanding 31.21M 1.475M 1.140M
Diluted Shares Outstanding 1.475M 1.140M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $291.1M $122.2M
YoY Change
Cash & Equivalents $291.1M $122.2M $46.97M
Short-Term Investments
Other Short-Term Assets $7.636M $1.353M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $298.7M $123.5M
YoY Change 647.7%
LONG-TERM ASSETS
Property, Plant & Equipment $6.261M $5.901M
YoY Change 106.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $872.0K $2.969M
YoY Change 61.18%
Total Long-Term Assets $7.133M $8.870M
YoY Change 99.36%
TOTAL ASSETS
Total Short-Term Assets $298.7M $123.5M
Total Long-Term Assets $7.133M $8.870M
Total Assets $305.8M $132.4M
YoY Change 602.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $706.0K $2.278M
YoY Change -55.93%
Accrued Expenses $6.013M $4.880M
YoY Change 242.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.719M $7.158M
YoY Change 100.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $396.0K $336.0K
YoY Change
Total Long-Term Liabilities $396.0K $336.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.719M $7.158M
Total Long-Term Liabilities $396.0K $336.0K
Total Liabilities $7.115M $7.497M
YoY Change 111.82%
SHAREHOLDERS EQUITY
Retained Earnings -$93.67M -$75.20M
YoY Change 120.34%
Common Stock $3.000K $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $298.7M -$72.59M -$33.05M
YoY Change
Total Liabilities & Shareholders Equity $305.8M $132.4M
YoY Change 602.63%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$18.45M -$14.43M -$6.990M
YoY Change 112.69% 106.44%
Depreciation, Depletion And Amortization $364.0K $300.0K $100.0K
YoY Change 271.43% 200.0%
Cash From Operating Activities -$20.54M -$14.08M -$5.645M
YoY Change 210.1% 149.34%
INVESTING ACTIVITIES
Capital Expenditures -$1.322M -$806.0K -$237.0K
YoY Change -8.89% 240.08%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$1.322M -$806.0K -$237.0K
YoY Change -8.89% 240.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.8M 106.0K 24.86M
YoY Change 127923.49% -99.57%
NET CHANGE
Cash From Operating Activities -20.54M -14.08M -5.645M
Cash From Investing Activities -1.322M -806.0K -237.0K
Cash From Financing Activities 190.8M 106.0K 24.86M
Net Change In Cash 168.9M -14.77M 18.98M
YoY Change -2230.86% -177.84%
FREE CASH FLOW
Cash From Operating Activities -$20.54M -$14.08M -$5.645M
Capital Expenditures -$1.322M -$806.0K -$237.0K
Free Cash Flow -$19.22M -$13.27M -$5.408M
YoY Change 271.53% 145.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.78
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.55
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1475170
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1139647
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1352721
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1078783
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
138821984
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
85299885
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1475170
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1139647
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1352721
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1078783
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.78
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.55
dei Entity Central Index Key
EntityCentralIndexKey
0001689375
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40969
dei Entity Registrant Name
EntityRegistrantName
ENTRADA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3983399
dei Entity Address Address Line1
EntityAddressAddressLine1
6 Tide Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
520-9158
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
TRDA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5901000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3037000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-42000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2969000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30321000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
541000
CY2021Q3 us-gaap Assets
Assets
132395000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-72591000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-41490000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132395000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31212856
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122172000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39045000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1353000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
904000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
123525000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
39949000
CY2021Q3 trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-66000
CY2020Q3 trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-17000
CY2020Q4 us-gaap Assets
Assets
43527000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2278000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1602000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4880000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1757000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7158000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3359000
CY2021Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
339000
CY2021Q3 us-gaap Liabilities
Liabilities
7497000
CY2020Q4 us-gaap Liabilities
Liabilities
3359000
CY2021Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
197489000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
81658000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
172000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113259306
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1684294
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1283545
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1547774
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1244139
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2631000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1021000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75222000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42511000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43527000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10513000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5700000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23564000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14446000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3851000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1273000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9103000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3568000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
14364000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
6973000
us-gaap Operating Expenses
OperatingExpenses
32667000
us-gaap Operating Expenses
OperatingExpenses
18014000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14364000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6973000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32667000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18014000
trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-44000
trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
164000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
164000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14430000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6990000
us-gaap Net Income Loss
NetIncomeLoss
-32711000
us-gaap Net Income Loss
NetIncomeLoss
-17850000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.78
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.55
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1475170
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1139647
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1352721
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1078783
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
37269149
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
31816000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-15518000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2020Q1 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
3000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
78000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4686000
CY2020Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
61284517
CY2020Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
56794000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-20122000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
83000
CY2020Q2 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
3000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
74000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6174000
CY2020Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
61284517
CY2020Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
56794000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-26136000
CY2020Q3 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
3000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6990000
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
85299885
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
81658000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-33048000
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
85299885
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
81658000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-41490000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2021Q1 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
8000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
164000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8380000
CY2021Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
138821984
CY2021Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
197489000
CY2021Q2 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
18000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
326000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
339000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-49669000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
212000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9901000
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
138821984
CY2021Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
197489000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-59014000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
106000
CY2021Q3 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
170000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
577000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14430000
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
138821984
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
197489000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-72591000
us-gaap Profit Loss
ProfitLoss
-32711000
us-gaap Profit Loss
ProfitLoss
-17850000
us-gaap Depreciation
Depreciation
753000
us-gaap Depreciation
Depreciation
228000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-153000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000
us-gaap Share Based Compensation
ShareBasedCompensation
1068000
us-gaap Share Based Compensation
ShareBasedCompensation
227000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
449000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1902000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1923000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
544000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
311000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
709000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2138000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
221000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18946000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3258000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
874000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3258000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-867000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
115831000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
49842000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
347000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
84000
trda Proceeds From Early Exercise Of Stock Options
ProceedsFromEarlyExerciseOfStockOptions
528000
trda Proceeds From Early Exercise Of Stock Options
ProceedsFromEarlyExerciseOfStockOptions
14000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
116706000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49940000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
83127000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30127000
CY2021Q3 trda Accrued Issuance Costs Current
AccruedIssuanceCostsCurrent
495000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
301000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
35000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
328000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4880000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39045000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16844000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122172000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46971000
trda Deferred Financing Costs In Accounts Payable And Accrued Expenses
DeferredFinancingCostsInAccountsPayableAndAccruedExpenses
505000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
832000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
616000
trda Vesting Of Restricted Stock Subject To Repurchase
VestingOfRestrictedStockSubjectToRepurchase
1000
trda Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
195000
trda Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
8000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14400000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7000000.0
us-gaap Net Income Loss
NetIncomeLoss
-32700000
us-gaap Net Income Loss
NetIncomeLoss
-17900000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75200000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122200000
CY2021Q3 trda Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
2200000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1757000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6953000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3414000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1052000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
377000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5901000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3037000
CY2021Q3 us-gaap Depreciation
Depreciation
300000
CY2020Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
800000
us-gaap Depreciation
Depreciation
200000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2752000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1482000
CY2021Q3 trda Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1004000
CY2020Q4 trda Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
125000
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
138821984
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
138821984
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
197489000
CY2021Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
204627000
CY2021Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
19185183
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
85299885
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
85299885
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
81658000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
88377000
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
11788435
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2021Q3 trda Number Of Directors Entitled To Be Elected
NumberOfDirectorsEntitledToBeElected
3
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
172000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113259306
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 trda Number Of Votes Per Share Of Common Stock
NumberOfVotesPerShareOfCommonStock
1
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19185183
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
578000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1068000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
227000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
136520
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
27869
CY2021Q3 trda Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
400000
CY2020Q4 trda Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
100000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1139647
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1352721
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14430000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6990000
us-gaap Net Income Loss
NetIncomeLoss
-32711000
us-gaap Net Income Loss
NetIncomeLoss
-17850000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1475170
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1078783
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.78
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.55
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21691266
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12851551

Files In Submission

Name View Source Status
0001558370-21-016637-index-headers.html Edgar Link pending
0001558370-21-016637-index.html Edgar Link pending
0001558370-21-016637.txt Edgar Link pending
0001558370-21-016637-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trda-20210930.xsd Edgar Link pending
trda-20210930x10q.htm Edgar Link pending
trda-20210930x10q_htm.xml Edgar Link completed
trda-20210930xex31d1.htm Edgar Link pending
trda-20210930xex31d2.htm Edgar Link pending
trda-20210930xex32d1.htm Edgar Link pending
trda-20210930_cal.xml Edgar Link unprocessable
trda-20210930_def.xml Edgar Link unprocessable
trda-20210930_lab.xml Edgar Link unprocessable
trda-20210930_pre.xml Edgar Link unprocessable